Expansion momentum Ivantis is now part of Alcon, signaling a potential cross-sell and integration opportunities with Alcon’s expanding manufacturing and product portfolio, especially as Alcon embarks on capacity investments in Fort Worth and other markets.

Strategic acquisitions Alcon’s recent acquisitions, including Neurotech Pharmaceuticals, indicate a growth strategy that may open collaboration avenues for advanced intraocular technologies and post-market clinical data partnerships.

New device launches The introduction of new intraocular lenses and enhanced ophthalmic solutions in multiple regions creates opportunities to position compatible surgical kits, accessories, and aftercare products across evolving cataract and refractive surgery workflows.

Clinical collaboration Alcon’s involvement in DEWS III and dry eye research partnerships suggests demand for supportive diagnostics, data capture, and patient management tools that align with evidence-based treatment programs.

Global reach With Alcon’s presence in 140 countries and a large employee base, there is potential to scale trials, training programs, and service offerings across new geographies leveraging existing distribution and support networks.